MEDIROM Healthcare Technologies Regains Compliance With NASDAQ Continued Listing Requirements
MEDIROM Healthcare Technologies Regains Compliance With NASDAQ Continued Listing Requirements
MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan ("MEDIROM" or the "Company"), today announced that on June 1, 2023, the Nasdaq Hearing Panel (the
總部位於日本的整體醫療保健公司（“MEDIROM” 或 “公司”）MEDIROM Healthcare Technologies Inc.（納斯達克股票代碼：MRM）今天宣佈，2023年6月1日，納斯達克聽證小組（
MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan ("MEDIROM" or the "Company"), today announced that on June 1, 2023, the Nasdaq Hearing Panel (the "Panel") notified the Company that it has regained compliance with the net income standard set forth in Nasdaq Listing Rule 5550(b)(3) and the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1), as evidenced by the filing of the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2022 on May 30, 2023. The Panel also advised that the Panel's oversight process of the Company is now closed. For more information regarding the Company's compliance with Nasdaq's continued listing requirements, please see the press release of the Company dated May 24, 2023, a copy of which was furnished as Exhibit 99.1 to a report on form 6-K filed by the Company with the SEC on May 24, 2023.
總部位於日本的整體醫療保健公司（“MEDIROM” 或 “公司”）MEDIROM Healthcare Technologies Inc.（納斯達克股票代碼：MRM）今天宣佈，2023年6月1日，納斯達克聽證小組（“小組”）通知公司，它已重新遵守納斯達克上市規則第5550（b）（3）條規定的淨收入標準以及納斯達克上市規則中規定的繼續上市的定期申報要求 5250 (c) (1)，公司於2023年5月30日提交的截至2022年12月31日財年的20-F表年度報告就證明了這一點。專家小組還告知，該小組對公司的監督程序現已結束。有關公司遵守納斯達克持續上市要求的更多信息，請參閱公司2023年5月24日的新聞稿，該新聞稿的副本作爲公司於2023年5月24日向美國證券交易委員會提交的6-K表報告的附錄99.1提供。
譯文內容由第三人軟體翻譯。